TR199903141T2 - Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi. - Google Patents

Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.

Info

Publication number
TR199903141T2
TR199903141T2 TR1999/03141T TR9903141T TR199903141T2 TR 199903141 T2 TR199903141 T2 TR 199903141T2 TR 1999/03141 T TR1999/03141 T TR 1999/03141T TR 9903141 T TR9903141 T TR 9903141T TR 199903141 T2 TR199903141 T2 TR 199903141T2
Authority
TR
Turkey
Prior art keywords
therapeutic protein
syndrome
blockade therapy
protein blocker
protein
Prior art date
Application number
TR1999/03141T
Other languages
English (en)
Turkish (tr)
Inventor
Adelman Burt
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR199903141T2 publication Critical patent/TR199903141T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
TR1999/03141T 1997-06-20 1998-06-19 Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi. TR199903141T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20

Publications (1)

Publication Number Publication Date
TR199903141T2 true TR199903141T2 (xx) 2000-09-21

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03141T TR199903141T2 (xx) 1997-06-20 1998-06-19 Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.

Country Status (25)

Country Link
US (1) US20020119151A1 (de)
EP (1) EP1034001B1 (de)
JP (1) JP2002504910A (de)
KR (1) KR100567998B1 (de)
CN (2) CN1261285A (de)
AT (1) ATE272408T1 (de)
AU (1) AU733062B2 (de)
BG (1) BG64436B1 (de)
BR (1) BR9810755A (de)
CA (1) CA2294138A1 (de)
CZ (1) CZ295805B6 (de)
DE (1) DE69825473T2 (de)
EA (1) EA002512B1 (de)
EE (1) EE9900587A (de)
ES (1) ES2226152T3 (de)
HK (1) HK1031825A1 (de)
HU (1) HUP0002048A3 (de)
IL (1) IL133305A0 (de)
IS (1) IS2097B (de)
NO (1) NO996274L (de)
NZ (1) NZ502051A (de)
PT (1) PT1034001E (de)
SK (1) SK285962B6 (de)
TR (1) TR199903141T2 (de)
WO (1) WO1998058672A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗cd154(cd40リガンド)抗体およびその使用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
EP2149585B1 (de) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen anti-CD40-monoklonale Antikörper
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗cd40抗体薬学的組成物
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l

Also Published As

Publication number Publication date
JP2002504910A (ja) 2002-02-12
HK1031825A1 (en) 2001-06-29
CA2294138A1 (en) 1998-12-30
SK285962B6 (sk) 2007-12-06
IS5274A (is) 1999-11-26
DE69825473T2 (de) 2005-08-04
CZ458899A3 (cs) 2000-04-12
EP1034001A1 (de) 2000-09-13
EA200000059A1 (ru) 2000-08-28
KR100567998B1 (ko) 2006-04-07
CN1651071A (zh) 2005-08-10
EA002512B1 (ru) 2002-06-27
BG64436B1 (en) 2005-02-28
IS2097B (is) 2006-04-12
NO996274D0 (no) 1999-12-17
KR20010013964A (ko) 2001-02-26
HUP0002048A2 (hu) 2000-10-28
EP1034001B1 (de) 2004-08-04
PT1034001E (pt) 2004-12-31
WO1998058672A1 (en) 1998-12-30
CZ295805B6 (cs) 2005-11-16
BR9810755A (pt) 2000-08-15
AU733062B2 (en) 2001-05-03
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
CN1261285A (zh) 2000-07-26
DE69825473D1 (de) 2004-09-09
ATE272408T1 (de) 2004-08-15
NO996274L (no) 2000-02-18
SK180399A3 (en) 2000-06-12
IL133305A0 (en) 2001-04-30
BG104092A (en) 2000-10-31
NZ502051A (en) 2001-04-27
AU8153698A (en) 1999-01-04
ES2226152T3 (es) 2005-03-16
US20020119151A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
TR199903141T2 (xx) Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
SE9800836D0 (sv) New Compounds
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2001062272A3 (en) Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
BR9909583A (pt) Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
GEP20053657B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds, Pharmaceutical Compositions Thereof
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
SE9802208D0 (sv) Novel compounds
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
SE9802209D0 (sv) Novel compounds
NO20006547L (no) Salter av paroxetine
SE8403659D0 (sv) Synergistic pharmaceutical composition
ATE258801T1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
MX9301537A (es) Composicion de resina de intercambio de iones.
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
SE9904483D0 (sv) New use
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
WO2001074341A3 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant